DelveInsight’s, “Liposarcoma Pipeline Insight 2025” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Liposarcoma pipeline landscape. It covers the Liposarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Liposarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead in the competitive pharmaceutical landscape with in-depth Liposarcoma Pipeline Insights! Discover the latest advancements, key Liposarcoma Companies driving innovation, and the most promising Emerging Drugs shaping the future of treatment. Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Liposarcoma Pipeline Outlook Report
Key Takeaways from the Liposarcoma Pipeline Report
- In March 2025, an open-label, non-randomized, multicenter trial enrolled patients with locally advanced or metastatic soft tissue sarcoma who had experienced disease progression within six months prior to enrollment.
- DelveInsight’s Liposarcoma pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Liposarcoma treatment.
- The leading Liposarcoma Companies such as Boehringer Ingelheim, Ascentage Pharma Group Inc., Edgewood Oncology Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Salarius Pharmaceuticals, LLC, Lamassu Bio Inc., Pfizer, Valo Therapeutics Oy, OncoResponse, Inc., Adaptimmune, Incyte Corporation, Daiichi Sankyo, Numab Therapeutics AG, HRYZ Biotech Co., Sotio Biotech Inc. and others.
- Promising Liposarcoma Therapies such as MGCD516, Mirdametinib, Palbociclib, Pazopanib, Efatutazone, Selinexor and others.
Uncover Liposarcoma groundbreaking developments in the drug pipeline with our latest report! Gain exclusive insights into Liposarcoma Clinical Trials, regulatory updates, and Emerging Drugs across multiple therapeutic areas. Learn how leading Liposarcoma Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!” @ Liposarcoma Clinical Trials Assessment
Liposarcoma Emerging Drugs Profile
- Brigimadlin: Boehringer Ingelheim
Brigimadlin is a potent, oral MDM2-p53 antagonist. Brigimadlin binds to MDM2 and blocks the MDM2–p53 interaction which prevents MDM2 from inactivating p53, thereby restoring p53 function. The MDM2 oncoprotein is a critical regulator of the tumor suppressor p53. Overexpression of MDM2 promotes p53 degradation and aids tumor proliferation. Preclinical study results have shown that brigimadlin had single-agent efficacy in MDM2-amplified DDLPS PDX models and improved responses/disease control in patient-derived xenografts and syngeneic mouse tumor models. Currently, the drug is in Phase III stage of its development for the treatment of Liposarcoma.
- APG-115: Ascentage Pharma Group Inc.
APG-115 is an orally administered, selective, small-molecule inhibitor of the MDM2-p53 PPI. APG-115 has strong binding affinity to MDM2 and is designed to activate p53 tumor suppression activity by blocking the MDM2-p53 PPI. Preclinical studies demonstrated that APG-115 promoted the production of proinflammatory cytokines in T cells, enhanced CD4+ T cell activation, and increased PD-L1 expression on various tumor cells. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Liposarcoma.
- CAR-GPC3 T Cells: Sotio Biotech Inc.
CAR-GPC3 T Cells, uniquely combine the GOT2 transgene of the proprietary BOXR platform, a critical enzyme involved in cellular metabolism, with CAR T technology targeting GPC3-expressing tumors. BOXR1030 is a next generation CAR T cell therapy which benefits from its enhanced T cell metabolism in the solid tumor microenvironment. CAR-GPC3 T Cells have demonstrated strong preclinical evidence in models that simulated the solid tumor microenvironment. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Liposarcoma.
- BTX-A51: Edgewood Oncology Inc.
BTX-A51 is a first-in-class, small molecule, multi-kinase inhibitor of casein kinase 1 alpha (CK1α), cyclin-dependent kinase 7 (CDK7) and CDK9 that synergistically co-targets master regulators of cancer to promote programmed cell death, or apoptosis. BTX-A51 has shown preclinical efficacy in treating patient-derived LPS in cell lines and human xenograft models and provides insight into the synergy gained by inhibiting both CK1a and CDK9. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Liposarcoma.
The Liposarcoma Pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Liposarcoma with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Liposarcoma Treatment.
- Liposarcoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Liposarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Liposarcoma market.
Explore the dynamic world of drug development with our latest Liposarcoma Pipeline Insights report! From early-stage research to late-phase Liposarcoma Clinical Trials, our analysis covers key Liposarcoma Companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don’t miss this opportunity to stay informed—download now! @ Liposarcoma Treatment Drugs
Liposarcoma Companies
Boehringer Ingelheim, Ascentage Pharma Group Inc., Edgewood Oncology Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Salarius Pharmaceuticals, LLC, Lamassu Bio Inc., Pfizer, Valo Therapeutics Oy, OncoResponse, Inc., Adaptimmune, Incyte Corporation, Daiichi Sankyo, Numab Therapeutics AG, HRYZ Biotech Co., Sotio Biotech Inc and others.
Liposarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
Liposarcoma Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
The future of medicine is evolving rapidly! Get detailed insights into ongoing Liposarcoma Clinical Trials, major Companies driving innovation, and the most anticipated Emerging Drugs in the pipeline. Stay updated with the latest Liposarcoma Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ Liposarcoma Market Drivers and Barriers, and Future Perspectives
Scope of the Liposarcoma Pipeline Report
- Coverage- Global
- Liposarcoma Companies- Boehringer Ingelheim, Ascentage Pharma Group Inc., Edgewood Oncology Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Salarius Pharmaceuticals, LLC, Lamassu Bio Inc., Pfizer, Valo Therapeutics Oy, OncoResponse, Inc., Adaptimmune, Incyte Corporation, Daiichi Sankyo, Numab Therapeutics AG, HRYZ Biotech Co., Sotio Biotech Inc. and others.
- Liposarcoma Therapies- MGCD516, Mirdametinib, Palbociclib, Pazopanib, Efatutazone, Selinexor and others.
- Liposarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Liposarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which Liposarcoma Emerging Drugs are set to revolutionize treatment landscapes? Which Liposarcoma Companies are leading the way in drug discovery? Find answers in our latest Liposarcoma Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!” @ Liposarcoma Emerging Drugs and Companies
Table of Content
- Introduction
- Executive Summary
- Liposarcoma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Liposarcoma – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Brigimadlin: Boehringer Ingelheim
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase I/II)
- APG-115: Ascentage Pharma Group Inc.
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- BTX-A51: Edgewood Oncology Inc.
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Liposarcoma Key Companies
- Liposarcoma Key Products
- Liposarcoma- Unmet Needs
- Liposarcoma- Market Drivers and Barriers
- Liposarcoma- Future Perspectives and Conclusion
- Liposarcoma Analyst Views
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight